Brief: FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis
13/09/2024 18:27
Sept 13 (Reuters) - Genentech:
* FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY
TWICE-A-YEAR
10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND
PROGRESSIVE MULTIPLE SCLEROSIS
Source text for Eikon: ID:nBw29jVlta
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets